BackCatabasis Pharmaceuticals Overview

Catabasis Pharmaceuticals Receivables

Latest receivables for CATB: $17M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$17.24M

Peer average

Loading

Catabasis Pharmaceuticals Receivables History

Loading

Catabasis Pharmaceuticals vs. peers: Receivables Comparison

Loading

Catabasis Pharmaceuticals Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Catabasis Pharmaceuticals (CATB) FAQ

Catabasis Pharmaceuticals (CATB) currently reports a receivables of $17M as of September 2025. Use the charts on this page to explore Catabasis Pharmaceuticals's receivables history and peer comparisons.

Catabasis Pharmaceuticals reported $17M in receivables as of September 2025. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $17M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Catabasis Pharmaceuticals, and consider following CATB for alerts when major investors trade the stock.

Catabasis Pharmaceuticals is classified in the Healthcare sector. On receivables, it currently shows $17M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CATB with unrelated industries.